Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies.
Pharmacol Rep
; 70(2): 284-293, 2018 Apr.
Article
in En
| MEDLINE
| ID: mdl-29477036
ABSTRACT
The prevalence of epilepsy is estimated 5-10 per 1000 population and around 70% of patients with epilepsy can be sufficiently controlled by antiepileptic drugs (AEDs). Epileptogenesis is the process responsible for converting normal into an epileptic brain and mechanisms responsible include among others inflammation, neurodegeneration, neurogenesis, neural reorganization and plasticity. Some AEDs may be antiepileptiogenic (diazepam, eslicarbazepine) but the correlation between neuroprotection and inhibition of epileptogenesis is not evident. Antiepileptogenic activity has been postulated for mTOR ligands, resveratrol and losartan. So far, clinical evidence gives some hope for levetiracetam as an AED inhibiting epileptogenesis in neurosurgical patients. Biomarkers for epileptogenesis are needed for the proper selection of patients for evaluation of potential antiepileptogenic compounds.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Epilepsy
/
Anticonvulsants
Type of study:
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Pharmacol Rep
Journal subject:
FARMACOLOGIA
Year:
2018
Document type:
Article
Affiliation country:
Poland